Our previous studies revealed that the GnRH-II antagonist Trp-1 inhibited proliferation and stimulated death signaling in human prostate cancer cells through mitochondrial dysfunction and autophagy [27], [28]. This evidence concerns the gene GNRH2 and prostate carcinoma.